Half of Young Hodgkin's Lymphoma Survivors Don't Get Proper Treatment

Less than half of all young adult and adolescent patients who survive Hodgkin's lymphoma get the recommended care after their first round of treatment, according to new research presented at the Cancer Survivorship Symposium in San Francisco this month.

Analyzing data about oncology visits, lab tests and CT scans, researchers identified how individuals between the ages of 15 and 39 were being treated after a Hodgkin's lymphoma diagnosis between 2000 and 2010.

"Patients treated for Hodgkin’s lymphoma are at high risk for recurrence and relapse, as well as serious long-term and late effects,” said Dr. Erin E. Hahn, research scientist at Kaiser Permanente.

Guideline adherence

While professional and medical organizations have specific guidelines about the care of Hodgkin's lymphoma survivors, how well these guidelines are followed is a topic that has not been studied, researchers said.

The study found that nearly all survivors were present at their recommended oncology appointments, yet only 70 percent received the recommended lab tests within the first 5 years of their initial treatment.

Two-thirds of patients received a CT scan within the first 12 months of treatment, but only 47 percent received a CT scan in year 2 and 35 percent received a scan in year 3.

In general, researchers concluded that only 48 percent of young adult survivors of Hodgkin's lymphoma receive all the medical care they should be getting within the first year of treatment.

“Ultimately, we want to make sure that these patients receive optimal care so that they can achieve optimal health outcomes,” Hahn said. “We have the opportunity to improve longer-term use of services. There is a need to improve care delivery, and our next steps are to think about designing and implementing systematic programs to address these needs.”

Source: Helio

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap